» Articles » PMID: 29383103

YAP Regulates PD-L1 Expression in Human NSCLC Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 Feb 1
PMID 29383103
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Programmed death-ligand 1 (PD-L1) is a membrane protein on tumor cells that binds to the PD-1 receptor expressed on immune cells, leading to the immune escape of tumor cells. Yes-associated protein (YAP) is a main effector of the Hippo/YAP signaling pathway, which plays important roles in cancer development. Here we show that YAP regulates PD-L1 expression in human non-small cell lung cancer (NSCLC) cells. First, we investigated YAP and PD-L1 expression at the protein level in 142 NSCLC samples and 15 normal lung samples. In tumor tissue, immunohistochemistry showed positive staining for YAP and PD-L1, which correlated significantly ( = 142, = 0.514, < 0.001). Second, in cell lines that express high levels of PD-L1 (H460, SKLU-1, and H1299), the ratio of p-YAP/YAP was lower and GTIIC reporter activity of the Hippo pathway was higher than those in three cell lines expressing low levels of PD-L1 (A549, H2030, and PC9) ( < 0.05). Third, in the same three cell lines, inhibition of YAP by two small interfering RNAs (siRNAs) decreased the mRNA and protein level of PD-L1 ( < 0.05). Fourth, forced overexpression of the YAP gene rescued the PD-L1 mRNA and protein level after siRNA knockdown targeting 3'UTR of the endogenous YAP gene. Finally, chromatin immunoprecipitation (ChIP) assays using a YAP-specific monoclonal antibody resulted in the precipitation of PD-L1 enhancer region encompassing two putative TEAD binding sites. Our results indicate that YAP regulates the transcription of PD-L1 in NSCLC.

Citing Articles

YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer.

Zhu Z, Ding R, Yu W, Liu Y, Zhou Z, Liu C Cell Death Differ. 2025; .

PMID: 39875519 DOI: 10.1038/s41418-025-01446-2.


Transient activation of YAP/TAZ confers resistance to morusin-induced apoptosis.

Lee H, Cho S, Cha H, Tae K, Choi C BMC Mol Cell Biol. 2025; 26(1):4.

PMID: 39833669 PMC: 11744988. DOI: 10.1186/s12860-025-00531-1.


Pan-cancer analysis of the prognostic and immunological role of hippo-YAP signaling pathway.

Yang J, Yang C, Yang G, Wang R, Li J, Song Y Discov Oncol. 2024; 15(1):504.

PMID: 39333438 PMC: 11436565. DOI: 10.1007/s12672-024-01212-9.


Targeted degradation of specific TEAD paralogs by small molecule degraders.

Chen H, Gridnev A, Schlamowitz N, Hu W, Dey K, Zheng G Heliyon. 2024; 10(18):e37829.

PMID: 39328531 PMC: 11425103. DOI: 10.1016/j.heliyon.2024.e37829.


Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review).

Taylor J, Dubois F, Bergot E, Levallet G Int J Oncol. 2024; 65(1).

PMID: 38785155 PMC: 11155713. DOI: 10.3892/ijo.2024.5656.


References
1.
Loke P, Allison J . PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003; 100(9):5336-41. PMC: 154346. DOI: 10.1073/pnas.0931259100. View

2.
Cooper W, Tran T, Vilain R, Madore J, Selinger C, Kohonen-Corish M . PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015; 89(2):181-8. DOI: 10.1016/j.lungcan.2015.05.007. View

3.
Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Chirieac L . Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(4):504-535. DOI: 10.6004/jnccn.2017.0050. View

4.
Bora-Singhal N, Nguyen J, Schaal C, Perumal D, Singh S, Coppola D . YAP1 Regulates OCT4 Activity and SOX2 Expression to Facilitate Self-Renewal and Vascular Mimicry of Stem-Like Cells. Stem Cells. 2015; 33(6):1705-18. PMC: 4441573. DOI: 10.1002/stem.1993. View

5.
Dai Y, Liu S, Zhang W, Yang Y, Hang P, Wang H . YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. Oncotarget. 2016; 8(3):4096-4109. PMC: 5354815. DOI: 10.18632/oncotarget.13686. View